NEW BRUNSWICK, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. (“Senesco” or the “Company”) today announced that, on November 16, 2009, Bruce C. Galton resigned from his position as a member of the board of directors. In addition, Mr. Galton resigned from his positions as the Company’s President and Chief Executive Officer to pursue other interests. Mr. Galton and the Company currently are discussing the terms of Mr. Galton’s separation with the Company.
Bruce Galton commented, “My goal has been to bring Senesco’s Factor 5A technology to the clinic to determine its utility to treat multiple myeloma, a serious bone marrow cancer. The Company is poised to initiate its pivotal toxicology study to support an IND application. It has been an honor and a pleasure to bring the Company to this point.”
Additional details regarding the foregoing are disclosed on the Company’s Form 8-K filed today.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability to successfully transition to new management; the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and joint ventures; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; success of the Company’s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Senesco Technologies, Inc.
